Moderna shares jumped nearly 177% in a single day after the company and Merck reported major success for their jointly developed personalized mRNA cancer vaccine in a Phase 3 clinical trial involving high-risk melanoma. The result was described as the world’s first proof of efficacy for an mRNA cancer therapy in a large Phase 3 trial. On Aug. 20, UBS raised its target price for Moderna (MRNA.O) from $50 to $150.